Amiko M Uchida, Sophia S Schuman, Ashley Pyne, Kathryn Peterson, Marie Carlson, John J Garber, Bjorn Roelstraete, Jonas F Ludvigsson
{"title":"Risk of Cancer Diagnosis in Patients With Eosinophilic Esophagitis Using a Nationwide Swedish Population Cohort.","authors":"Amiko M Uchida, Sophia S Schuman, Ashley Pyne, Kathryn Peterson, Marie Carlson, John J Garber, Bjorn Roelstraete, Jonas F Ludvigsson","doi":"10.1002/ueg2.12713","DOIUrl":"https://doi.org/10.1002/ueg2.12713","url":null,"abstract":"<p><strong>Background: </strong>Eosinophilic esophagitis (EoE) is a chronic, inflammatory disease of the esophagus. Chronic inflammation has been linked to cancer development. We aimed to study the potential association between EoE and later cancer diagnosis.</p><p><strong>Methods: </strong>In this nationwide population-based cohort study, we identified 1580 individuals with EoE diagnosed between 1990-2017 through Sweden's 28 pathology departments. Up to five general population reference individuals were matched on age and sex (n = 7533). A Cox regression analysis estimated adjusted hazard ratios (aHRs) for cancer up until December 31, 2020. To reduce potential intrafamilial confounding, we also compared EoE individuals with their unaffected siblings.</p><p><strong>Results: </strong>During a median follow-up of 7 years, 47 individuals with EoE (3.9/1000 person-years) developed cancer versus 183 (3.2/1000 person-years) reference individuals. This corresponded to a non-significant aHR of 1.11 (95% CI = 0.80-1.53). Incidence rates were independent of budesonide and proton-pump inhibitor use. Individuals with EoE however did have an increased risk of esophageal cancer where two EoE versus one reference individual were diagnosed (aHR = 25.20; 95% CI = 2.28-278.80), and also Barrett's esophagus risk was also increased in EoE (HR = 18.18; 95% CI = 6.75-48.95). Non-esophageal gastrointestinal (GI) cancer occurred in 11 EoE versus 24 reference individuals: aHR = 2.03 (95% CI = 0.99-4.18). We found no increased risk of cancers from the skin (EoE n = 10), lung (n = 0), breast (n = 4), or blood (n = 0). Sibling analyses supported these findings.</p><p><strong>Conclusion: </strong>We did not find any overall association between EoE and cancer development. EoE was associated with esophageal cancer, but this was very rare with wide confidence interval and few cases therefore we urge caution with generalization of these findings.</p>","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142677198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Expanding Support Beyond Clinical Care in IBD Patients.","authors":"Zhonglei Shen, Sheng Li","doi":"10.1002/ueg2.12715","DOIUrl":"10.1002/ueg2.12715","url":null,"abstract":"<p><strong>Introduction: </strong>A rational discussion of the impact of Pain, Fatigue and Bowel Incontinence on the Quality of Life of People Living With Inflammatory Bowel Disease: A UK Cross- Sectional Survey.</p><p><strong>Conclusion: </strong>To help Inflammatory Bowel Disease patients manage symptoms and improve quality of life by incorporating a multifaceted community health strategy that goes beyond routine symptomatic treatment.</p>","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142669009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Louis Onghena, Yves van Nieuwenhove, Hans Van Vlierberghe, Lindsey Devisscher, Sarah Raevens, Xavier Verhelst, Sander Lefere, Anja Geerts
{"title":"Prior metabolic and bariatric surgery is an independent determinant of severity of decompensation in alcohol-associated liver disease.","authors":"Louis Onghena, Yves van Nieuwenhove, Hans Van Vlierberghe, Lindsey Devisscher, Sarah Raevens, Xavier Verhelst, Sander Lefere, Anja Geerts","doi":"10.1002/ueg2.12642","DOIUrl":"https://doi.org/10.1002/ueg2.12642","url":null,"abstract":"<p><strong>Background: </strong>Patients with a history of metabolic and bariatric surgery (MBS) are susceptible to developing alcohol use disorder, potentially resulting in end-stage liver disease, with a paucity of data on the evolution of cirrhosis.</p><p><strong>Aims: </strong>Our aim was to describe the demographics and mortality in hospitalizations over time in individuals diagnosed with cirrhosis due to alcohol-associated liver disease (ALD) in relation to prior MBS.</p><p><strong>Methods: </strong>We included patients hospitalized at the Ghent University Hospital between 1/1/2010 and 01/09/2023 with cirrhosis due to ALD. Data were retrieved retrospectively from all hospitalizations.</p><p><strong>Results: </strong>46/275 (16.7%) of individuals with cirrhosis admitted with ALD had a history of MBS; they were predominantly female (76.1%), in contrast to the non-MBS population (29.7%) (p < 0.0001) and were significantly younger at the time of diagnosis (46 vs. 58 years, p < 0.0001). Liver disease evolved at a faster pace in the MBS group with a shorter time to first hospitalization (5 vs. 13 months, p = 0.036), and consecutive hospitalizations. The proportion with primary hospitalization due to acute-on-chronic liver failure (ACLF) was significantly larger in the MBS group (60.9% vs. 27.6%, p < 0.0001), and throughout the following hospitalizations, ACLF remained more prevalent in the MBS group. Modeled transplant-free survival was lower in the MBS group (p = 0.004), with ACLF as the main cause of death. The weekly amount of alcohol consumed during drinking periods and duration of use were significantly lower in the MBS group.</p><p><strong>Conclusions: </strong>MBS patients hospitalized with ALD develop acute decompensation at a faster pace, with more overall ACLF hospitalizations, and higher cumulative mortality, despite being 12 years younger on average.</p><p><strong>Clinical trial registration: </strong>Not applicable.</p>","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142640048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Matteo Tacelli, Stefano Partelli, Massimo Falconi, Paolo Giorgio Arcidiacono, Gabriele Capurso
{"title":"Pancreatic Neuroendocrine Neoplasms: Classification and Novel Role of Endoscopic Ultrasound in Diagnosis and Treatment Personalization.","authors":"Matteo Tacelli, Stefano Partelli, Massimo Falconi, Paolo Giorgio Arcidiacono, Gabriele Capurso","doi":"10.1002/ueg2.12710","DOIUrl":"https://doi.org/10.1002/ueg2.12710","url":null,"abstract":"<p><p>The incidence and prevalence of pancreatic neuroendocrine neoplasms are steadily increasing. These tumors are highly heterogeneous, with treatment options ranging from observation to surgery, and various medical therapies. The choice of treatment is influenced by factors such as tumor stage, grade (proliferative activity), and the presence of hormone-related syndromes. Endoscopic ultrasound (EUS) is becoming increasingly valuable for assessing pancreatic neuroendocrine neoplasms, offering detailed morphological, vascular, and functional information through techniques such as contrast enhancement and elastography. It also allows biopsies that are useful for both histopathological and molecular analyses. These tumors are highly heterogeneous, with treatment options ranging from observation to various medical therapies and surgery. Recent data suggest that small, non-functioning PanNENs with low proliferation rates may be safely monitored, whereas more aggressive or functioning tumors typically require surgery. EUS-guided ablation is a promising alternative for patients with functional pancreatic neuroendocrine neoplasms who are unsuitable for surgery, although randomized trials are needed. In non-resectable pancreatic neuroendocrine neoplasms, treatment options include somatostatin analogs, targeted therapies (e.g., everolimus, sunitinib), chemotherapy, and radioligand therapy. This review discusses key factors in planning personalized treatment strategies for pancreatic neuroendocrine neoplasms.</p>","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142629448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yuhong Yuan, Rocio Sedano, Virginia Solitano, Olga Maria Nardone, Eileen Crowley, Vipul Jairath
{"title":"Heterogeneity of definition of upper gastrointestinal tract in different guidelines of Crohn's disease: A scoping review.","authors":"Yuhong Yuan, Rocio Sedano, Virginia Solitano, Olga Maria Nardone, Eileen Crowley, Vipul Jairath","doi":"10.1002/ueg2.12697","DOIUrl":"https://doi.org/10.1002/ueg2.12697","url":null,"abstract":"<p><p>Crohn's Disease (CD) can affect any part of the gastrointestinal (GI) tract, including the upper GI tract (UGIT). However, the definitions and classifications of upper GI CD (UGICD) vary. We conducted a scoping review to explore how UGIT and UGICD are defined and to assess the heterogeneity of these definitions in published CD guidelines, aiming to inform future initiatives for harmonizing definitions. We conducted a search of MEDLINE and Embase for English-language guidelines on CD that mentioned upper GI-related terms in the titles, abstracts, or keywords from inception until 26 July 2024. Definitions of UGIT and UGICD were summarized descriptively. Of 1132 citations, only 19 records met our inclusion criteria. Only eight were identified as CD guidelines. None of them focuses on UGICD. Among these, five diagnostic guidelines explicitly mentioned \"upper GI\" in their abstracts. Only the joint European Crohn's and Colitis Organisation and European Society of Gastrointestinal and Abdominal Radiology guidelines clearly defined the UGIT. Most guidelines mentioned UGI terms related to upper endoscopy or biopsy only. It was unclear whether these guidelines typically included the esophagus, stomach, and duodenum in the definition of UGICD while excluding the distal small intestine. Although the latest guideline related to pediatric-onset IBD cited the 2011 Paris classification, none of the three guidelines published after that explicitly mentioned the proposed subdivided location of the upper disease. There is a lack of consistent reporting in defining UGICD according to disease location. It is unclear whether there is a consensus on excluding the small intestine beyond the duodenum. Additionally, there is no indication that the subdivided location of UGIT was considered in CD guideline development. Greater consistency in definitions would aid in diagnosis, clinical care, epidemiological research and inclusion into clinical trials. These findings underscore the need for developing a framework to standardize the classification of UGICD, especially for clinical trials.</p>","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142629446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alica K Beutel, Menar Ekizce, Thomas J Ettrich, Thomas Seufferlein, Jessica Lindenmayer, Johann Gout, Alexander Kleger
{"title":"Organoid-based precision medicine in pancreatic cancer.","authors":"Alica K Beutel, Menar Ekizce, Thomas J Ettrich, Thomas Seufferlein, Jessica Lindenmayer, Johann Gout, Alexander Kleger","doi":"10.1002/ueg2.12701","DOIUrl":"https://doi.org/10.1002/ueg2.12701","url":null,"abstract":"<p><p>Pancreatic ductal adenocarcinoma (PDAC) ranks among the leading causes of cancer-related deaths worldwide. Despite advances in precision oncology in other malignancies, treatment of PDAC still largely relies on conventional chemotherapy. Given the dismal prognosis and heterogeneity in PDAC, there is an urgent need for personalized therapeutic strategies to improve treatment response. Organoids, generated from patients' tumor tissue, have emerged as a powerful tool in cancer research. These three-dimensional models faithfully recapitulate the morphological and genetic features of the parental tumor and retain patient-specific heterogeneity. This review summarizes existing precision oncology approaches in PDAC, explores current applications and limitations of organoid cultures in personalized medicine, details preclinical studies correlating in vitro organoid prediction and patient treatment response, and provides an overview of ongoing organoid-based clinical trials.</p>","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142629447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Upadacitinib Versus Filgotinib in Ulcerative Colitis: Is the Evidence Sufficient to Inform Treatment Decisions?","authors":"Sudheer Kumar Vuyyuru, Yuhong Yuan, Vipul Jairath","doi":"10.1002/ueg2.12709","DOIUrl":"https://doi.org/10.1002/ueg2.12709","url":null,"abstract":"","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142629450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Bugs and germs in GI-disease.","authors":"","doi":"10.1002/ueg2.12693","DOIUrl":"https://doi.org/10.1002/ueg2.12693","url":null,"abstract":"","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142629444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Real-World Comparative Effectiveness and Safety of Filgotinib and Upadacitinib for Ulcerative Colitis: A Multicentre Cohort Study.","authors":"Akira Nogami, Kunio Asonuma, Shinji Okabayashi, Maiko Ikenouchi, Takahisa Matsuda, Shinichiro Shinzaki, Masayuki Fukata, Taku Kobayashi","doi":"10.1002/ueg2.12704","DOIUrl":"https://doi.org/10.1002/ueg2.12704","url":null,"abstract":"<p><strong>Background: </strong>Janus kinase (JAK) inhibitors, filgotinib (FIL) and upadacitinib (UPA) have emerged as promising treatments for ulcerative colitis (UC). However, a comparative analysis of these JAK inhibitors, particularly in patients previously treated with tofacitinib (TOF), has not been performed.</p><p><strong>Aims: </strong>To compare the efficacy and safety of FIL and UPA in patients with UC, including those previously exposed to TOF.</p><p><strong>Methods: </strong>A multicentre retrospective cohort study was conducted to compare the effectiveness and safety of FIL and UPA in patients with UC whose treatment was initiated between March 2022 and December 2023. The co-primary outcomes were clinical response and remission at week 8. The secondary outcomes included treatment persistence and adverse events (AEs). Modified Poisson and Cox regression models with multivariable analysis to adjust for confounders and propensity score matching were conducted. Subgroup analyses stratified by previous exposure to TOF and biologics were also conducted.</p><p><strong>Results: </strong>In total, 168 patients (98 treated with FIL and 70 treated with UPA) were enrolled in this study, with a median follow-up period of 181 days. The clinical response/remission rates at week 8 were 55.1/46.9% for FIL and 71.4/65.7% for UPA, respectively. UPA was associated with significantly higher rates of clinical response (adjusted risk ratio [RR] 1.40 [95% confidence interval [CI], 1.09 to 1.80]) and clinical remission (adjusted RR 1.54 [95% CI, 1.16 to 2.05]) compared with FIL. This result was consistent across subgroup analyses based on previous exposure to TOF or biologics, except for bio-naive patients. There was no significant difference in the treatment persistence. AEs were more frequent with UPA (45.7%) than with FIL (24.5%) (p = 0.0049). Propensity score matching confirmed the superior overall effectiveness of UPA.</p><p><strong>Conclusions: </strong>UPA demonstrated better short-term effectiveness than FIL, with a higher incidence of AEs.</p>","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142629449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Emilio J Laserna-Mendieta, Sergio Casabona-Francés, Edurne Amorena, Edoardo V Savarino, Isabel Pérez-Martínez, Leonardo Blas-Jhon, Antonio Guardiola-Arévalo, Marina Coletta, Gaia Pellegatta, Danila Guagnozzi, Jesús Barrio, Antonia Perello, Elena Betoré, Anne Lund Krarup, Martina Votto, Carolina Gutiérrez-Junquera, Juan Enrique Naves, Salvatore Oliva, Carlos Teruel Sánchez-Vegazo, Silvia Carrión, Susana de la Riva, Silvia Espina-Cadenas, Sonia Fernández-Fernández, Mónica Llorente-Barrio, Irene Pascual-Lopez, María Luisa Masiques-Mas, Raúl Honrubia-López, Raffaella Dainese, Natalia García-Morales, Julyssa Cobian, Juan Khaled Bisso-Zein, Valentín Roales, Alba Juan-Juan, Alba Rodríguez-Sánchez, Sara Feo-Ortega, Verónica Martín-Domínguez, Óscar Nantes-Castillejo, Julia Nicolay-Maneru, Matteo Ghisa, Daria Maniero, Adolfo Suarez, Iván Maray, Marta Álvarez-García, Alicia Granja-Navacerrada, Roberto Penagini, Francesca Racca, Ronald Llerena-Castro, Cecilio Santander, Ángel Arias, Alfredo J Lucendo
{"title":"Sex-related differences in the presentation, management and response to treatment of eosinophilic esophagitis: Cross sectional analysis of EoE CONNECT registry.","authors":"Emilio J Laserna-Mendieta, Sergio Casabona-Francés, Edurne Amorena, Edoardo V Savarino, Isabel Pérez-Martínez, Leonardo Blas-Jhon, Antonio Guardiola-Arévalo, Marina Coletta, Gaia Pellegatta, Danila Guagnozzi, Jesús Barrio, Antonia Perello, Elena Betoré, Anne Lund Krarup, Martina Votto, Carolina Gutiérrez-Junquera, Juan Enrique Naves, Salvatore Oliva, Carlos Teruel Sánchez-Vegazo, Silvia Carrión, Susana de la Riva, Silvia Espina-Cadenas, Sonia Fernández-Fernández, Mónica Llorente-Barrio, Irene Pascual-Lopez, María Luisa Masiques-Mas, Raúl Honrubia-López, Raffaella Dainese, Natalia García-Morales, Julyssa Cobian, Juan Khaled Bisso-Zein, Valentín Roales, Alba Juan-Juan, Alba Rodríguez-Sánchez, Sara Feo-Ortega, Verónica Martín-Domínguez, Óscar Nantes-Castillejo, Julia Nicolay-Maneru, Matteo Ghisa, Daria Maniero, Adolfo Suarez, Iván Maray, Marta Álvarez-García, Alicia Granja-Navacerrada, Roberto Penagini, Francesca Racca, Ronald Llerena-Castro, Cecilio Santander, Ángel Arias, Alfredo J Lucendo","doi":"10.1002/ueg2.12699","DOIUrl":"https://doi.org/10.1002/ueg2.12699","url":null,"abstract":"<p><strong>Background: </strong>Eosinophilic esophagitis (EoE) predominantly affects males across all ages; however, little is known about sex differences for other aspects of EoE.</p><p><strong>Objective: </strong>To investigate associations between sex and clinical presentation, endoscopic features, treatment choice and response in EoE patients in real-world practice.</p><p><strong>Methods: </strong>Cross-sectional analysis of the multicenter EoE CONNECT registry. The independent contribution of patients' sex and other relevant variables were statistically assessed by multivariate models.</p><p><strong>Results: </strong>A total of 2976 patients (76% male) were evaluated. Males were diagnosed at a younger age compared to females (32.7 ± 14.8 vs. 34.8 ± 15.6 years, respectively; p = 0.002) with similar diagnostic delay. EoE symptoms varied significantly between sexes, with food impaction predominating in males and dysphagia, heartburn, regurgitation and abdominal and epigastric pain in females. However, female sex contributed to higher symptom severity at diagnosis as measured with Dysphagia Symptom Score (R<sup>2</sup> = 0.57; p = 0.013) and presented higher peak eosinophil count in esophageal biopsies (p = 0.005). Males showed increased risk of stricturing or mixed phenotypes (adjusted OR 1.43, 95%CI:1.05-1.96; p = 0.024). No association was found between patients' sex and first-line treatment modality: proton pump inhibitors (PPI) were preferred over topical corticosteroids in patients with inflammatory phenotypes instead of stricturing or mixed phenotypes, and in patients who did not present food impaction. Both topical corticosteroids and dietary interventions were preferred over PPI in pediatric patients regardless of sex.</p><p><strong>Conclusions: </strong>Sex is associated with clinical and phenotypical presentation of EoE at diagnosis, with more fibrotic findings in males but higher symptom score in females.</p>","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}